Rocket Pharmaceuticals (RCKT) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Environment Environmental Environmental Protection Lifecycle Materials Nature Net Zero Nuclear Offset Package Packaging Pandemic Regenerative Toxic Access African American Asian Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Data Privacy Data Security Death Demographic Disability Diversity Drug Pricing Employee Employee Training Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injury Latinx LGBTQ Minority Pay Equity Perquisites Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Supplier Supply Chain Talent Training Union Women Workers Workforce Assessment Assurance Attorneys General Audit Bonus Chronic Classified Clawback Commitment Conflict of Interest Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Overboarding Oversee Oversight Perquisite Plaintiff Pledging Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Single Trigger Strategy Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

PX14A6G

RCKT Rocket Pharmaceuticals Inc

29 May 20

Letter to shareholders

10:56am

Vote support at last AGM

The 2022 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the “Company”), was held on June 13, 2022 (the “Annual Meeting”). At the Annual Meeting, there were present, in person or by proxy, holders of 55,510,402 shares of common stock, or approximately 86.03% of the total outstanding shares eligible to be voted. The holders present voted on the three proposals presented at the Annual Meeting as follows.

Proposal One - Election of Directors

The Company’s stockholders approved the election of nine directors to the Company’s Board of Directors (“Board”) by the following votes:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Elisabeth Björk, M.D., Ph.D.	47,847,554	561,549	7,101,299
Carsten Boess	47,072,823	1,336,280	7,101,299
Pedro Granadillo	43,070,107	5,338,996	7,101,299
Gotham Makker, M.D.	41,028,492	7,380,611	7,101,299
Fady Malik, M.D., Ph.D.	48,162,602	246,501	7,101,299
Gaurav Shah, M.D.	41,608,251	6,800,852	7,101,299
David P. Southwell	36,115,931	12,293,172	7,101,299
Roderick Wong, M.D.	40,759,519	7,649,584	7,101,299
Naveen Yalamanchi, M.D.	36,921,225	11,487,878	7,101,299

Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm

The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2022 by the following votes:

Votes For		Votes Against		Abstentions
55,475,923		30,029		4,450

Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the 2022 Annual Meeting of Stockholders pursuant to Section 14A of the Exchange Act, including the Compensation Discussion and Analysis, the Summary Compensation Table, and the narrative disclosures that accompany the compensation tables. The final votes were:

Votes For		Votes Against		Abstentions		Broker Non-Votes
42,160,877		6,240,249		7,977		7,101,299